COST-EFFECTIVENESS OF SWITCHING PATIENTS EITH TYPE 2 DIABETES FROM INSULIN GLARGINE TO INSULIN DETEMIR IN A CHINESE SETTING: A HEALTH ECONOMIC MODEL BASED ON THE PREDICTIVE STUDY

Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective

Permsuwan, Unchalee
Thavorn, Kednapa
Dilokthornsakul, Piyameth
Saokaew, Surasak
Chaiyakunapruk, Nathorn

September 2017

An economic evidence is a vital tool that can inform the decision to use costly insulin analogs. Thi...

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China

Gu, Shuyan
Mu, Yiming
Zhai, Suodi
Zeng, Yuhang
Zhen, Xuemei
Dong, Hengjin

January 2016

Objective To estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monothera...

Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes

Xiaoling Cai (319173)
Lizheng Shi (289790)
Wenjia Yang (2865512)
Shuyan Gu (736892)
Yingyao Chen (3466658)
Lin Nie (366551)
Linong Ji (131708)

March 2019

Background and objective: Dapagliflozin is the first SGLT2 inhibitor available in China, where the d...

EVALUATING THE COST-EFFECTIVENESS OF SWITCHING FROM INSULIN GLARGINE TO INSULIN DETEMIR IN PATIENTS WITH TYPE-2 DIABETES IN A CHINESE SETTING: A MODELING STUDY BASED ON THE PREDICTIVE STUDY

Yang, L.
Lay, A. L.
Chang, J. H.

January 2011

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAM...

Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study

Yang, Li
Christensen, Torsten
Sun, Fengyu
Chang, Jinghua

January 2012

Objectives: To evaluate the long-term cost-effectiveness of switching from insulin glargine (IGla) t...

Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study

Yang, Li
Christensen, Torsten
Sun, Fengyu
Chang, Jinghua

February 2012

AbstractObjectivesTo evaluate the long-term cost-effectiveness of switching from insulin glargine (I...

Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea

Lee, Kyoung Hee
Seo, Se Jin
Smith-Palmer, Jayne
Palmer, James L.
White, Jeremy
Valentine, William J.

December 2009

ABSTRACTObjectivesTo estimate the cost-effectiveness of switching patients with poorly controlled ty...

Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly ControlledType 2

Diabetes In South Koreavhe_
William J. Valentine

October 2016

Objectives: To estimate the cost-effectiveness of switching patients with poorly controlled type 2 d...

Developing a health economic model for Asians with type 2 diabetes based on the Japan Diabetes Complications Study and the Japanese Elderly Diabetes Intervention Trial

Shiro Tanaka
Ryo Kawasaki
Lars Wilkinson
Kazuya Fujihara
Hirohito Sone
Tatsumi Moriya
Jakob Langer
Tim Morton
Nicki Hoskins
Sachiko Tanaka-Mizuno
Chika Horikawa
Rei Aida
Atsushi Araki

August 2021

Introduction Cost-effectiveness analyses are becoming increasingly important in Japan following the ...

Cost-Utility Analysis of Intensive Blood Glucose Control with Metformin versus Usual Care in Overweight Type 2 Diabetes Mellitus Patients in Beijing, P.R. China

Xie, Xuanqian
Vondeling, Hindrik

January 2008

Objective: The UKPDS 34 and 51 showed that intensive blood glucose control with metformin is cost-sa...

Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials

Darbà, Josep
Ascanio, Meritxell
Carvalho, Davide
Conde, Vasco
Pedersen, Kasper S.

June 2020

Objectives: To assess the cost-effectiveness of insulin degludec (degludec) versus insulin glargine ...

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China

Gu Shuyan
Mu Yiming
Zhai Suodi
Zeng Yuhang
Zhen Xuemei
Dong Hengjin

November 2016

To estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monotherapy in trea...

The Cost-Effectiveness of Lifestyle Interventions for Preventing Diabetes in a Health Resource-Limited Setting

Jing Ma
Xu Wan
Bin Wu

January 2020

Aims. Type 2 diabetes mellitus (T2DM) is a health challenge in China, and the economic outcomes of l...

EVALUATING SHORT-TERM COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS ORAL ANTIDIABETIC DRUGS IN PATIENTS WITH TYPE 2 DIABETES IN A CHINESE SETTING

Shi, L. W.
Han, S.
Sun, F.
Liu, F.

January 2013

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAM...

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.

Shuyan Gu
Yiming Mu
Suodi Zhai
Yuhang Zeng
Xuemei Zhen
Hengjin Dong

January 2016

OBJECTIVE:To estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monothera...

Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective

Permsuwan, Unchalee
Thavorn, Kednapa
Dilokthornsakul, Piyameth
Saokaew, Surasak
Chaiyakunapruk, Nathorn

September 2017

An economic evidence is a vital tool that can inform the decision to use costly insulin analogs. Thi...

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China

Gu, Shuyan
Mu, Yiming
Zhai, Suodi
Zeng, Yuhang
Zhen, Xuemei
Dong, Hengjin

January 2016

Objective To estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monothera...

Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes

Xiaoling Cai (319173)
Lizheng Shi (289790)
Wenjia Yang (2865512)
Shuyan Gu (736892)
Yingyao Chen (3466658)
Lin Nie (366551)
Linong Ji (131708)

March 2019

Background and objective: Dapagliflozin is the first SGLT2 inhibitor available in China, where the d...

EVALUATING THE COST-EFFECTIVENESS OF SWITCHING FROM INSULIN GLARGINE TO INSULIN DETEMIR IN PATIENTS WITH TYPE-2 DIABETES IN A CHINESE SETTING: A MODELING STUDY BASED ON THE PREDICTIVE STUDY

Yang, L.
Lay, A. L.
Chang, J. H.

January 2011

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAM...

Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study

Yang, Li
Christensen, Torsten
Sun, Fengyu
Chang, Jinghua

January 2012

Objectives: To evaluate the long-term cost-effectiveness of switching from insulin glargine (IGla) t...

Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study

Yang, Li
Christensen, Torsten
Sun, Fengyu
Chang, Jinghua

February 2012

AbstractObjectivesTo evaluate the long-term cost-effectiveness of switching from insulin glargine (I...

Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea

Lee, Kyoung Hee
Seo, Se Jin
Smith-Palmer, Jayne
Palmer, James L.
White, Jeremy
Valentine, William J.

December 2009

ABSTRACTObjectivesTo estimate the cost-effectiveness of switching patients with poorly controlled ty...

Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly ControlledType 2

Diabetes In South Koreavhe_
William J. Valentine

October 2016

Objectives: To estimate the cost-effectiveness of switching patients with poorly controlled type 2 d...

Developing a health economic model for Asians with type 2 diabetes based on the Japan Diabetes Complications Study and the Japanese Elderly Diabetes Intervention Trial

Shiro Tanaka
Ryo Kawasaki
Lars Wilkinson
Kazuya Fujihara
Hirohito Sone
Tatsumi Moriya
Jakob Langer
Tim Morton
Nicki Hoskins
Sachiko Tanaka-Mizuno
Chika Horikawa
Rei Aida
Atsushi Araki

August 2021

Introduction Cost-effectiveness analyses are becoming increasingly important in Japan following the ...

Cost-Utility Analysis of Intensive Blood Glucose Control with Metformin versus Usual Care in Overweight Type 2 Diabetes Mellitus Patients in Beijing, P.R. China

Xie, Xuanqian
Vondeling, Hindrik

January 2008

Objective: The UKPDS 34 and 51 showed that intensive blood glucose control with metformin is cost-sa...

Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials

Darbà, Josep
Ascanio, Meritxell
Carvalho, Davide
Conde, Vasco
Pedersen, Kasper S.

June 2020

Objectives: To assess the cost-effectiveness of insulin degludec (degludec) versus insulin glargine ...

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China

Gu Shuyan
Mu Yiming
Zhai Suodi
Zeng Yuhang
Zhen Xuemei
Dong Hengjin

November 2016

To estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monotherapy in trea...

The Cost-Effectiveness of Lifestyle Interventions for Preventing Diabetes in a Health Resource-Limited Setting

Jing Ma
Xu Wan
Bin Wu

January 2020

Aims. Type 2 diabetes mellitus (T2DM) is a health challenge in China, and the economic outcomes of l...

EVALUATING SHORT-TERM COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS ORAL ANTIDIABETIC DRUGS IN PATIENTS WITH TYPE 2 DIABETES IN A CHINESE SETTING

Shi, L. W.
Han, S.
Sun, F.
Liu, F.

January 2013

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAM...

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.

Shuyan Gu
Yiming Mu
Suodi Zhai
Yuhang Zeng
Xuemei Zhen
Hengjin Dong

January 2016

OBJECTIVE:To estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monothera...

Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective

Permsuwan, Unchalee
Thavorn, Kednapa
Dilokthornsakul, Piyameth
Saokaew, Surasak
Chaiyakunapruk, Nathorn

September 2017

An economic evidence is a vital tool that can inform the decision to use costly insulin analogs. Thi...

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China

Gu, Shuyan
Mu, Yiming
Zhai, Suodi
Zeng, Yuhang
Zhen, Xuemei
Dong, Hengjin

January 2016

Objective To estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monothera...

Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes

Xiaoling Cai (319173)
Lizheng Shi (289790)
Wenjia Yang (2865512)
Shuyan Gu (736892)
Yingyao Chen (3466658)
Lin Nie (366551)
Linong Ji (131708)

March 2019

Background and objective: Dapagliflozin is the first SGLT2 inhibitor available in China, where the d...

COST-EFFECTIVENESS OF SWITCHING PATIENTS EITH TYPE 2 DIABETES FROM INSULIN GLARGINE TO INSULIN DETEMIR IN A CHINESE SETTING: A HEALTH ECONOMIC MODEL BASED ON THE PREDICTIVE STUDY

Abstract

Extracted data

COST-EFFECTIVENESS OF SWITCHING PATIENTS EITH TYPE 2 DIABETES FROM INSULIN GLARGINE TO INSULIN DETEMIR IN A CHINESE SETTING: A HEALTH ECONOMIC MODEL BASED ON THE PREDICTIVE STUDY

Abstract

Extracted data

Related items

Related items